Actively Recruiting
Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis
Led by Glostrup University Hospital, Copenhagen · Updated on 2026-01-28
220
Participants Needed
1
Research Sites
128 weeks
Total Duration
On this page
Sponsors
G
Glostrup University Hospital, Copenhagen
Lead Sponsor
U
University of Copenhagen
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study, iPROACT-MS, is part of the iPROACT group of clinical trials aiming to investigate the effects of oral supplementation with indole-3-propionic acid (IPA) in humans. IPA is naturally produced as a gut bacterial metabolite with the amino acid tryptophan as substrate. The primary aim of iPROACT-MS is to investigate whether patients with relapsing-remitting multiple sclerosis (RRMS) can benefit from supplementation with IPA. The hypothesis is that supplementation with IPA will protect against MS-related disease activity, neurodegeneration and metabolic abnormalities. Secondary, iPROACT-MS aims at elucidating the complex relationships between lifestyle, gut microbial factors, inflammation, oxidative stress, metabolic health, MS disease severity and MS disease activity.
CONDITIONS
Official Title
Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women and men 63518 and 6365 years of age
- Diagnosed with RRMS according to the 2017 McDonald criteria (or newer updates)
- Routinely treated and monitored for MS
- Speak and read Danish
- Deemed physically and mentally able to participate in this study
You will not qualify if you...
-
Active malignancy
-
Diagnosis of Crohn's disease and ulcerative colitis
-
Other comorbidities deemed to be relevant
-
Haematopoietic stem cell transplantation
-
Current or past treatment with non-MS related treatments deemed to be relevant
-
Pregnancy or lactation
-
People with MR contraindications:
-
Severe claustrophobia
-
Incompatible implants/ foreign objects, including implanted pacemakers, heart valve prostheses, prostheses in the middle ear, implanted devices (e.g., insulin pump), metal debris, e.g., metal splinters in the eyes, miscellaneous shunts and catheters, metal clips from operations
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Glostrup Hospital
Glostrup Municipality, Denmark, 2600
Actively Recruiting
Research Team
J
Jette Lautrup Frederiksen, MD, dr.med, professor
CONTACT
M
Moschoula Passali, MSc, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here